We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review).
- Authors
Jin, Ning; Xia, Yu; Gao, Qinglei
- Abstract
With the development of precision medicine, targeted therapy has attracted extensive attention. Poly(ADP-ribose) polymerase inhibitors (PARPi) are critical clinical drugs designed to induce cell death and are major antitumor targeted agents. However, preclinical and clinical data have revealed the limitations of PARPi monotherapy. Therefore, their combination with other targeted drugs has become a research hotspot in tumor treatment. Recent studies have demonstrated the critical role of small molecular inhibitors in multiple haematological cancers and solid tumors via cellular signalling modulation, exhibiting potential as a combined pharmacotherapy. In the present review, studies focused on small molecular inhibitors targeting the homologous recombination pathway were summarized and clinical trials evaluating the safety and efficacy of combined treatment were discussed.
- Publication
International Journal of Oncology, 2023, Vol 62, Issue 2, pN.PAG
- ISSN
1019-6439
- Publication type
Article
- DOI
10.3892/ijo.2023.5476